Telbivudine (Tyzeka) Outdoes Adefovir (Hepsera) in Reducing HBV Viral Loads
May 2nd, 2007 Posted by: Dr. Cox
HONG KONG, Oct. 2 — In a head-to-head comparison in patients with chronic hepatitis B, telbivudine (Tyzeka) reduced viral loads more effectively than adefovir (Hepsera), researchers here said. Action Points
Explain to interested patients that chronic Hepatitis B can lead to cirrhosis and liver cancer, and higher risk is associated with high levels of viral DNA in the bloodstream.
Note that this study compared two antiviral drugs and found that telbivudine (Tyzeka) did better than adefovir (Hepsera) at reducing viral loads.
Note also that the study duration did not allow assessment of long term efficacy or clinical outcomes.
In an open-label study over 24 weeks, telbivudine reduced viral loads by more than a factor of 10 compared with adefovir, a difference that was significant at P